Government Patent Rights

The Bayh-Dole Act of 1980 transformed the commercialization of federally funded research: HISTORICAL CONTEXT: before Bayh-Dole, the federal government retained title to most inventions made with federal funding; these patents were generally not commercialized — companies would not invest in developing products based on technology they did not own; by 1980, only 5% of the 28,000+ federally funded patents had been licensed; BAYH-DOLE HOLDING: Public Law 96-517 (codified at 35 U.S.C. §§ 200-212): universities; small businesses; and nonprofits may elect to retain title to inventions made in the performance of federally funded research; the contractor must: disclose the invention to the funding agency; elect title within 2 years of disclosure (or earlier if required by the funding agreement); file a patent application (if title is elected) within 1 year of election; report utilization of the invention to the agency; ELIGIBILITY: the act applies to: universities and colleges; nonprofit research institutions; small businesses (< 500 employees per SBA definition); large businesses may be covered by agency-specific regulations (DFARS for defense contracts) or separate regulations; RESULT: Bayh-Dole transformed university technology transfer; university patent licensing grew from ~250 patents in 1980 to 10,000+ annually by 2010; major technology companies traced to federally funded university research include Google (NSF-funded Stanford research), Genentech, and many biotech companies; Stanford v. Roche (S.Ct. 2011): important limitation — Bayh-Dole does NOT automatically vest invention rights in the university; the individual inventor still has initial ownership; Bayh-Dole only gives the university the OPTION to elect title; the university must actually get the inventor to ASSIGN the invention (via IAA); a researcher who assigned rights to a company BEFORE the university's IAA was signed gave valid title to the company (Roche).

Even when a contractor elects to retain title, the government retains significant rights: GOVERNMENT LICENSE (§ 202(c)(4)): the government retains a royalty-free, nonexclusive, nontransferable, irrevocable license to practice the invention for or on behalf of the United States throughout the world; 'GOVERNMENT PURPOSE LICENSE' SCOPE: the government can make, use, and sell the invention for GOVERNMENT purposes; this includes use by contractors working for the government if the contract specifies government purposes; what is NOT included: the government cannot license to commercial parties for commercial use; cannot sell to competitors of the contractor for their own commercial use; MARCH-IN RIGHTS (§ 203): the funding agency has the right to require the contractor to grant a license (or may grant such a license itself) to a 'responsible applicant' if: (1) the contractor (or assignee) has not taken effective steps to achieve practical application of the invention within a reasonable time; (2) action is necessary to alleviate health or safety needs not reasonably satisfied by the contractor; (3) action is necessary to meet requirements for public use specified by Federal regulations; (4) the contractor has not complied with US-manufacture preference (§ 204); MARCH-IN RIGHTS IN PRACTICE: march-in rights have been petitioned but NEVER actually exercised by any federal agency as of 2026; in 2004, NIH received a petition to march-in on HIV drug Norvir over drug pricing — NIH declined; the government has consistently declined to use march-in to address drug pricing, finding that drug pricing is not a ground for march-in; US MANUFACTURE PREFERENCE (§ 204): products incorporating Bayh-Dole inventions must be 'substantially manufactured in the United States'; this requirement can be waived by the funding agency.

Bayh-Dole compliance requires active management of invention disclosure and reporting: INVENTION DISCLOSURE OBLIGATIONS: researchers must promptly disclose any 'subject invention' (invention made under federal funding) to their institution's technology transfer office; the institution must disclose to the funding agency within 2 months of the employee's disclosure (or as specified in the funding agreement); what triggers disclosure: any invention 'conceived or first actually reduced to practice' in the performance of work under a federally funded grant; a partial use of federal funds (even for equipment purchased with federal money) can trigger Bayh-Dole; iEDISON REPORTING SYSTEM: NIH, NSF, DOE, and other agencies use the iEdison database for Bayh-Dole compliance reporting; institutions must report: invention disclosures; election of title decisions; patent applications filed; licenses granted; commercial products derived from the invention; annual utilization reports; FUNDING AGREEMENT PROVISIONS: each federal funding agreement (grant or contract) includes standard patent rights clauses (37 C.F.R. § 401.14); these specify: disclosure timelines; title election procedures; government license; march-in right retention; US manufacture preference; PRACTICAL COMPLIANCE TIPS: have a robust invention disclosure form that researchers complete; make sure all researchers covered by federal grants understand the disclosure obligation; label all federal grant numbers in lab notebooks; review all funding agreements before signing to understand Bayh-Dole scope; WAIVER OF BAYH-DOLE RIGHTS: a contractor can waive their right to elect title; the government may also retain title for national security reasons or in certain classified research; SMALL BUSINESS vs. LARGE BUSINESS: the standard Bayh-Dole provisions apply to small businesses by statute; large businesses are covered by agency regulations (notably DFARS for Defense contracts; FAR Part 27 for civilian agencies).

Bayh-Dole creates specific constraints and opportunities for spinouts from federally funded research: COMMON STARTUP SCENARIO: a professor at a state university conducts NIH-funded research that leads to a promising therapy; the university's TTO licenses the technology to a startup formed by the professor; BAYH-DOLE CONSTRAINTS ON THE STARTUP: the startup (as licensee of the Bayh-Dole invention) is subject to: GOVERNMENT LICENSE: the government's royalty-free non-exclusive license to practice the invention for government purposes is retained in the startup's license — this cannot be negotiated away; MARCH-IN RISK: if the startup fails to develop the technology and commercialize it within a reasonable time, NIH could (theoretically) invoke march-in rights to require the startup to license others; US MANUFACTURE PREFERENCE: the startup's products should be substantially manufactured in the US (waivable with agency approval); UTILIZATION REPORTING: the startup must provide commercialization progress reports; SPECIFIC OBLIGATIONS BY AGENCY: NIH: most biotech startups deal with NIH-funded inventions; NIH requires annual utilization reports; has not exercised march-in rights to date; DOE: energy technology inventions; similar Bayh-Dole provisions; DARPA: research contracts (not grants) for defense; often uses a different model (contractor may retain rights with government purpose license or government may retain broader rights depending on the program); NSF: academic research; similar to NIH; DUE DILIGENCE FOR INVESTORS: investors in university spinouts should review the underlying funding agreements; identify all federal grants that contributed to the invention (even partially); understand the government's license and march-in rights as a risk factor; confirm the university properly perfected title (Stanford v. Roche problem — was the IAA signed before any outside assignment?); EXCLUSIVE LICENSE STRUCTURE: the startup typically gets an exclusive license (not an assignment of the patent from the university); the license should specify: government license retention; US manufacture preference compliance; utilization reporting obligations; sub-licensing rights.

The federal government is one of the largest patent owners in the world, separate from Bayh-Dole: GOVERNMENT-OWNED PATENTS: agencies like the Department of Defense, NASA, NIH (NCI), NIST, DOE National Laboratories, and USDA own patents developed by federal employees (not contractors); GOVERNMENT EMPLOYEE INVENTIONS: 35 U.S.C. § 207: government agencies may apply for, obtain, and hold patents; 35 U.S.C. § 208: agencies may grant licenses to government patents; government employees have rights to their inventions in limited circumstances but typically must assign to the agency; GOVERNMENT PATENT LICENSING PROGRAMS: NASA: Technology Transfer Program; licenses NASA patents and spin-off technologies; NIST: National Technology Transfer Center; DOE National Labs: Lawrence Berkeley, Argonne, Oak Ridge, etc. own thousands of patents; license through lab technology transfer offices; NIH: Intramural Research Program patents; licensed through NIH Office of Technology Transfer; GOVERNMENT LICENSE TO CONTRACTORS: under DFARS (Defense Federal Acquisition Regulations) and FAR Part 27 for civilian contracts: LARGE BUSINESS CONTRACTORS: the government may take title to inventions made under certain DOD contracts; the contractor may get a license back; the default vs. 'exceptional circumstances' distinction: for most R&D contracts, contractor retains title (Bayh-Dole-like for small business; negotiated for large business); CLASSIFIED INVENTIONS: classified inventions (national security) can be handled under special procedures; secrecy orders can prevent patent publication and enforce confidentiality; §§ 181-188; STEVENSON-WYDLER ACT (§ 200): Federal laboratories must actively transfer federally developed technology to non-federal parties; technology transfer is a statutory mandate for federal labs, not just a discretionary activity.